{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:27:52Z","timestamp":1792682872281,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.1001\/jamadermatol.2020.0932","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T13:00:32Z","timestamp":1586955632000},"page":"668","source":"Crossref","is-referenced-by-count":65,"title":["Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris"],"prefix":"10.1001","volume":"156","author":[{"given":"Dylan","family":"Haynes","sequence":"first","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Strunck","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Topham","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex G.","family":"Ortega-Loayza","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Kent","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela B.","family":"Cassidy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghua","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Choate","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuangang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri M.","family":"Greiling","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"doi200019r1","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2016.0091","article-title":"Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients.","volume":"152","author":"Ross","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi200019r2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2230.1980.tb01676.x","article-title":"Pityriasis rubra pilaris.","volume":"5","author":"Griffiths","year":"1980","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"doi200019r3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.1995.tb06939.x","article-title":"Pityriasis rubra pilaris and human immunodeficiency virus infection.","volume":"133","author":"Miralles","year":"1995","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi200019r4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ajhg.2012.05.010","article-title":"Familial pityriasis rubra pilaris is caused by mutations in CARD14.","volume":"91","author":"Fuchs-Telem","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"2","key":"doi200019r5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaad.2019.01.061","article-title":"Pityriasis rubra pilaris: a study evaluating patient quality of life in 2 populations.","volume":"81","author":"Eastham","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi200019r6","first-page":"243","article-title":"Systemic therapies of pityriasis rubra pilaris: a systematic review.","volume":"17","author":"Kromer","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"doi200019r7","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12559","article-title":"Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: a retrospective investigation.","volume":"30","author":"Maloney","year":"2017","journal-title":"Dermatol Ther"},{"issue":"8","key":"doi200019r8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/ddg.13550","article-title":"Refractory pityriasis rubra pilaris with good response after treatment with ustekinumab.","volume":"16","author":"Arag\u00f3n-Miguel","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"doi200019r9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jdcr.2017.09.010","article-title":"Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl.","volume":"4","author":"Bonomo","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"6","key":"doi200019r10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/ced.13626","article-title":"Erythrodermic pityriasis rubra pilaris managed at home: intensive community care followed by ustekinumab.","volume":"43","author":"Ismail","year":"2018","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"doi200019r11","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12577","article-title":"A case of juvenile pityriasis rubra pilaris type III successfully treated with etanercept.","volume":"31","author":"Lora","year":"2018","journal-title":"Dermatol Ther"},{"issue":"2","key":"doi200019r12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/1346-8138.14114","article-title":"Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases.","volume":"45","author":"Napolitano","year":"2018","journal-title":"J Dermatol"},{"issue":"2","key":"doi200019r13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000488902","article-title":"Successful treatment of pityriasis rubra pilaris with ixekizumab.","volume":"10","author":"Hanfstingl","year":"2018","journal-title":"Case Rep Dermatol"},{"issue":"8","key":"doi200019r14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jdcr.2018.05.006","article-title":"Successful treatment of type I pityriasis rubra pilaris with ixekizumab.","volume":"4","author":"Heibel","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"6","key":"doi200019r15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jdcr.2016.09.006","article-title":"Successful treatment of type II pityriasis rubra pilaris with secukinumab.","volume":"2","author":"Gauci","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"11","key":"doi200019r16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamadermatol.2016.3885","article-title":"Successful treatment of refractory pityriasis rubra pilaris with secukinumab.","volume":"152","author":"Schuster","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi200019r17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1684\/ejd.2019.3502","article-title":"Successful treatment of TNFa inhibitor-resistant pityriasis rubra pilaris with ixekizumab and acitretin.","volume":"29","author":"Chastagner","year":"2019","journal-title":"Eur J Dermatol"},{"key":"doi200019r18","article-title":"Successful treatment of pityriasis rubra pilaris with brodalumab.","author":"De Rosa","year":"2019","journal-title":"Australas J Dermatol"},{"issue":"4","key":"doi200019r19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamadermatol.2016.5384","article-title":"Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris.","volume":"153","author":"Feldmeyer","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"9993","key":"doi200019r20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"doi200019r21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis.","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"doi200019r22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000250744","article-title":"Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359.","volume":"158","author":"Fredriksson","year":"1979","journal-title":"Dermatologica"},{"issue":"2","key":"doi200019r23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi200019r24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"doi200019r25","first-page":"997","article-title":"The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results.","volume":"159","author":"Basra","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi200019r26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: What do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi200019r27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/09546630310019382","article-title":"A quantitative definition of severe psoriasis for use in clinical trials.","volume":"15","author":"Feldman","year":"2004","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"doi200019r28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","article-title":"The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis.","volume":"210","author":"Schmitt","year":"2005","journal-title":"Dermatology"},{"issue":"5","key":"doi200019r29","first-page":"630","article-title":"Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy.","volume":"20","author":"Ruiz Villaverde","year":"2010","journal-title":"Eur J Dermatol"},{"issue":"1","key":"doi200019r30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.","volume":"130","author":"Krueger","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"doi200019r31","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ajhg.2012.03.013","article-title":"Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis.","volume":"90","author":"Jordan","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"5","key":"doi200019r32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajhg.2012.03.012","article-title":"PSORS2 is due to mutations in CARD14.","volume":"90","author":"Jordan","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"3","key":"doi200019r33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jaad.2018.02.034","article-title":"CARD14-associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris.","volume":"79","author":"Craiglow","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"doi200019r34","article-title":"Histopathologic findings characteristic of CARD14-associated papulosquamous eruption.","author":"Ring","year":"2019","journal-title":"J Cutan Pathol"},{"issue":"9","key":"doi200019r35","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jid.2018.03.1525","article-title":"CARD14 gain-of-function mutation alone is sufficient to drive IL-23\/IL-17-mediated psoriasiform skin inflammation in vivo.","volume":"138","author":"Mellett","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi200019r36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","article-title":"Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? a systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.","volume":"66","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"doi200019r37","volume-title":"A phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate to Severe Atopic Dermatitis","author":"Regeneron Pharmaceuticals, Inc","year":"2016"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2764605\/jamadermatology_haynes_2020_oi_200019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T22:11:30Z","timestamp":1722723090000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2764605"}},"subtitle":["A Single-Arm Trial"],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.0932","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}